MX2023002350A - Composiciones y metodos para mejorar enfermedades y trastornos neurologicos. - Google Patents
Composiciones y metodos para mejorar enfermedades y trastornos neurologicos.Info
- Publication number
- MX2023002350A MX2023002350A MX2023002350A MX2023002350A MX2023002350A MX 2023002350 A MX2023002350 A MX 2023002350A MX 2023002350 A MX2023002350 A MX 2023002350A MX 2023002350 A MX2023002350 A MX 2023002350A MX 2023002350 A MX2023002350 A MX 2023002350A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- disorders
- neurological diseases
- patient
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 208000012902 Nervous system disease Diseases 0.000 title 2
- 208000025966 Neurological disease Diseases 0.000 title 2
- 239000000556 agonist Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000019771 cognition Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
- A61B6/03—Computed tomography [CT]
- A61B6/037—Emission tomography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
- A61B6/501—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications for diagnosis of the head, e.g. neuroimaging or craniography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Optics & Photonics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- High Energy & Nuclear Physics (AREA)
- Surgery (AREA)
- Dentistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063073353P | 2020-09-01 | 2020-09-01 | |
| US202163212077P | 2021-06-17 | 2021-06-17 | |
| PCT/US2021/048540 WO2022051305A1 (en) | 2020-09-01 | 2021-08-31 | Compositions and methods for improving neurological diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002350A true MX2023002350A (es) | 2023-04-26 |
Family
ID=80491939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002350A MX2023002350A (es) | 2020-09-01 | 2021-08-31 | Composiciones y metodos para mejorar enfermedades y trastornos neurologicos. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230263749A1 (https=) |
| EP (1) | EP4208159A4 (https=) |
| JP (1) | JP2023541379A (https=) |
| KR (1) | KR20230107211A (https=) |
| AU (1) | AU2021337583A1 (https=) |
| CA (1) | CA3189243A1 (https=) |
| MX (1) | MX2023002350A (https=) |
| WO (1) | WO2022051305A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022185255A1 (en) | 2021-03-03 | 2022-09-09 | Lenovo (Singapore) Pte. Ltd. | Beam failure detection using multiple sets of reference signals |
| WO2024137506A1 (en) * | 2022-12-21 | 2024-06-27 | Curasen Therapeutics, Inc. | Compositions and methods for improving neurological diseases and disorders |
| US20250107713A1 (en) * | 2023-09-29 | 2025-04-03 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and Methods for Confirming Iboga Alkaloid Treatment |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3952101A (en) * | 1975-04-14 | 1976-04-20 | Smithkline Corporation | α-Amino methyl-5-hydroxy-2-pyridinemethanols |
| NZ226991A (en) * | 1987-11-27 | 1992-03-26 | Merck & Co Inc | Alpha-heterocyclically-substituted ethanolamines and use as animal growth promotors |
| US5264459A (en) * | 1992-07-13 | 1993-11-23 | Arch Development Corporation | Use of β-adrenergic agonists to treat patients with demyelinating or autoimmune diseases |
| GB2356197A (en) * | 1999-10-12 | 2001-05-16 | Merck & Co Inc | Amide derivatives as beta 3 agonists |
| CN1469876A (zh) * | 2000-10-20 | 2004-01-21 | �Ʒ� | α-芳基乙醇胺及其用作β-3肾上腺素能受体激动剂的用途 |
| US20080033027A1 (en) * | 2005-03-21 | 2008-02-07 | Vicus Therapeutics Spe 1, Llc | Drug combination pharmaceutical compositions and methods for using them |
| US9320724B2 (en) * | 2013-02-13 | 2016-04-26 | The Board Of Trustees Of The Leland Stanford Junior University | Method of improving cognition and increasing dendritic complexity in humans with down syndrome and compositions therefor |
| WO2018195473A1 (en) * | 2017-04-20 | 2018-10-25 | The Brigham And Women's Hospital, Inc. | Combinations including beta-adrenoreceptor agonists for treatment of parkinson's disease and movement disorders |
| CA3100848A1 (en) * | 2018-06-14 | 2019-12-19 | Curasen Therapeutics, Inc. | Methods for improving neurological diseases and disorders |
| EP3806957A4 (en) * | 2018-06-14 | 2022-03-16 | Curasen Therapeutics, Inc. | METHODS OF DIAGNOSIS, MONITORING AND TREATMENT OF NEUROLOGICAL DISEASES AND DISORDERS |
| JP7682097B2 (ja) * | 2019-03-27 | 2025-05-23 | キュラセン セラピューティクス インコーポレイテッド | ベータアドレナリンアゴニスト及びそれを使用する方法 |
| WO2021081292A1 (en) * | 2019-10-25 | 2021-04-29 | Curasen Therapeutics, Inc. | METHODS FOR TREATING NEUROLOGICAL DISORDERS WITH α1A-AR PARTIAL AGONISTS |
| CA3161376A1 (en) * | 2019-12-18 | 2021-06-24 | Anthony P. FORD | Methods for improving neurological diseases and disorders |
| MX2022015165A (es) * | 2020-06-04 | 2023-03-01 | Curasen Therapeutics Inc | Formas y composiciones de un agonista beta adrenégico. |
-
2021
- 2021-08-31 WO PCT/US2021/048540 patent/WO2022051305A1/en not_active Ceased
- 2021-08-31 AU AU2021337583A patent/AU2021337583A1/en active Pending
- 2021-08-31 MX MX2023002350A patent/MX2023002350A/es unknown
- 2021-08-31 KR KR1020237010888A patent/KR20230107211A/ko active Pending
- 2021-08-31 JP JP2023513936A patent/JP2023541379A/ja active Pending
- 2021-08-31 EP EP21865003.4A patent/EP4208159A4/en active Pending
- 2021-08-31 US US18/023,693 patent/US20230263749A1/en active Pending
- 2021-08-31 CA CA3189243A patent/CA3189243A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230263749A1 (en) | 2023-08-24 |
| JP2023541379A (ja) | 2023-10-02 |
| KR20230107211A (ko) | 2023-07-14 |
| AU2021337583A1 (en) | 2023-05-04 |
| WO2022051305A1 (en) | 2022-03-10 |
| EP4208159A1 (en) | 2023-07-12 |
| EP4208159A4 (en) | 2024-09-25 |
| AU2021337583A9 (en) | 2024-06-27 |
| CA3189243A1 (en) | 2022-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021021979A3 (en) | Hdac6 inhibitors and uses thereof | |
| MX2023002350A (es) | Composiciones y metodos para mejorar enfermedades y trastornos neurologicos. | |
| MX2011007854A (es) | Metodos para tratar infartos agudos al miocardio y trastornos relacionados. | |
| ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| EA201490163A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. | |
| JOP20220259A1 (ar) | تركيبات تشتمل على جسيمات نانونية، طريقة تصنيعها واستخدامها | |
| PH12021553102A1 (en) | Methods of treating fabry disease in patients having renal impairment | |
| JOP20210324A1 (ar) | مشتقات من 2h-indazole واستخدامها في علاج مرض | |
| MA55199B1 (fr) | (n-)acétyl-l-leucine pour le traitement des lésions cérébrales traumatiques | |
| MX2023003348A (es) | Compuestos y composiciones como moduladores de señalización tlr. | |
| EA202193190A1 (ru) | Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов | |
| MX2024014117A (es) | Sales de ácido piperidinil-metil-purina-amina-d-tartárico, formas cristalinas y su uso en el tratamiento de enfermedades y condiciones médicas | |
| CA2986891C (en) | Compositions for use in treating parkinson's disease and related disorders | |
| MX2023001296A (es) | Composiciones y metodos para tratar enfermedades y trastornos. | |
| PH12022552447A1 (en) | Nlrp3 modulators | |
| EP4357334A3 (en) | Conjugated oligonucleotide compounds, methods of making and uses thereof | |
| WO2020219486A3 (en) | Collagen peptide-based medicament compositions and devices and methods of production and use thereof | |
| MX2023000610A (es) | Inhibidor de trpv4 como agente terapeutico para enfermedades oculares. | |
| WO2023043870A8 (en) | Chewing gum formulation of lsd and methods of use thereof | |
| MX2025014320A (es) | Compuestos nitrogenados aromaticos, metodos de preparacion y usos medicinales | |
| MX2025000673A (es) | Metodos de administracion de nalbufina | |
| MX2025002727A (es) | Escilo-inositol en combinación con inmunoterapéuticos para el tratamiento de la enfermedad de alzheimer | |
| MX2024001269A (es) | Inhibidores de rock2 y sus usos. | |
| JOP20240081A1 (ar) | مُعدِّلات الجزيئات الصغيرة لنشاط الجلوكوسيريبروسيد واستخداماتها |